

ASX ANNOUNCEMENT

Partnership with leading virtual care platform eCare21 in US

- Signed Letter of Intent, to integrate HeraCARE and HeraBEAT into eCare21 platform
- eCare21 is a leading telehealth and remote monitoring platform, marketed in collaboration and powered by Dell Technologies
- The partnership is expected to accelerate awareness and take-up of HeraCARE and HeraBEAT in the US market
- Integrated solution expected to be rolled-out in the coming months and made available to eCare21's customer base of healthcare providers
- Partnership complements existing strategy of driving adoption through clinical validation and endorsement by key opinion leaders

HeraMED Limited (ASX:HMD) ("HeraMED" or the "Company"), a medical data and technology company leading the digital transformation of maternity care with its proprietary in-home maternity care platform, is pleased to announce it has signed a Letter of intent ("LOI") with leading provider of virtual care, eCare21, to integrate its technology into the eCare21 platform. HeraMED and ecare21 will immediately progress to finalising a binding commercial agreement.

eCare21 is an established, US-based, virtual care platform that combines telehealth and remote patient monitoring into an integrated SaaS solution, enabling an end-to-end solution for virtual care. eCare21, powered by Dell Technologies ensures providers can give patients access to remote care and analyze patient data, enabling better patient care and outcomes. eCare21 allows providers to manage chronic conditions remotely and streamlines provider and patient communications to help avert acute medical events.

eCare21 has a large and established customer base of healthcare providers, focusing on patients with chronic conditions, who subscribe to its virtual care platform. This collaboration with HeraMED reflects eCare21's intention to strengthen its platform with the addition of a maternal health monitoring solution. eCare21's Community of Care features will enable family members to remotely engage in the care of the mother and baby throughout the pregnancy and beyond.

As part of this partnership, HeraMED's HeraCARE platform, including its clinically validated in-home foetal and maternal heart rate monitor HeraBEAT, will be fully integrated into the eCare21 platform. The integrated solution which is expected to simplify the deployment of virtual care for maternal health patients and providers is expected to be available by the end of 2020.

The eCare21 collaboration represents progress in HeraMED's execution of its well-defined commercialisation strategy in the USA, providing HeraMED access to a large number of healthcare providers that have experience using remote monitoring services. This partnership complements HeraMED's existing strategy of obtaining clinical validation and endorsement by key opinion leaders, to support adoption of the HeraCARE platform by globally recognised healthcare providers such as the Mayo clinic.

The onset of COVID-19 has presented a unique opportunity to fast-track the adoption of digital health in maternity care. HMD is well-placed to deliver high-quality, prenatal, and postpartum care to improve the safety, efficiency, and cost of maternal healthcare. HMD continues to receive significant interest from prospects from around the world and is well-placed to capitalise on these opportunities.



HeraMED CEO and Cofounder Mr David Groberman, said: "We are delighted to be partnering with such a credible and well-established virtual care operator as eCare21. The integration of the HeraCARE platform into the eCare21 platform is expected to result in a rapid take up of HeraCARE across healthcare providers."

eCare21's Founder and CEO, Vadim Cherdak, PhD, said: "We are confident that the eCare21 platform, combined with HeraMED's unique and proprietary pregnancy monitoring solutions will create one of the best connected health solutions on the market."

This announcement has been authorised by the Board of HeraMED Limited.

-ENDS-

HeraMED Limited CEO and Co-Founder David Groberman M: +972 52 6991188

E: David@hera-med.com

Company Secretary Jonathan Hart T: +61 2 8379 2961

E: Jonathan@hera-med.com

Media Enquiries Melissa Hamilton Media & Capital Partners

M: +61 4 1775 0274

E: Melissa.hamilton@mcpartners.com.au

About HeraMED Limited (ASX:HMD):

HeraMED is an innovative medical date and technology company leading the digital transformation of maternity care by revolutionising the prenatal and postpartum experience with its hybrid maternity care platform. HeraMED offers a proprietary platform that utilises hardware and software to reshape the Doctor/Patient relationship using its clinically validated in-home foetal and maternal heart rate monitor, HeraBEAT, cloud computing, artificial intelligence, big data and a digital social networking dashboard.

About HeraCARE

The Company's proprietary offering, HeraCARE, has been engineered to offer a fully integrated maternal health ecosystem designed to deliver better care at a lower cost, ensure expectant mothers are engaged, informed and well-supported, allow healthcare professionals to provide the highest quality care and enable early detection and prevention of potential risks.

About eCare21

eCare21 (eCare21.com) is a patient-centric Virtual Care Platform that combines Telehealth and Remote Patient Monitoring into a unified SaaS solution across the entire continuum of care. eCare21 is the first end-to-end solution for Virtual Care that creates a seamless workflow for delivering healthcare in the home to improve patient outcomes and automatically translates the patient encounter into a billable event for the provider. For more details on the eCare21 Virtual Care Solution Powered by Dell Technologies please visit the following website for a short video:

https://www.delltechnologies.com/en-

us/events/himss20/index.htm?dgc=SM&cid=25271&lid=spr3282103901&linkld=86709812#scroll=off&tab0=1&video-overlay=6147450660001&accordion0&accordion1&accordion2&accordion3